Aurinia Pharmaceuticals Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending September 30, 2025. The company achieved net product sales of $70.6 million for the third quarter, a 27% increase from $55.5 million in the same period last year. For the nine months ended September 30, 2025, net product sales reached $197.2 million, up 24% from $158.6 million in 2024. Total revenue for the third quarter was $73.5 million, compared to $67.8 million in the prior year, while year-to-date revenue increased to $205.9 million from $175.3 million.
Operating expenses for the third quarter decreased to $43.7 million from $56.0 million in the same quarter of 2024, primarily due to a reduction in selling, general, and administrative expenses, which fell from $42.4 million to $26.2 million. This reduction reflects the impact of strategic restructuring efforts initiated in 2024, which included a significant reduction in headcount. The company reported a net income of $31.6 million for the third quarter, compared to $14.4 million in the same period last year, marking a substantial turnaround in profitability.
Aurinia's operational developments include the ongoing commercialization of LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for lupus nephritis, which has seen increased adoption in the market. The company sells LUPKYNIS through two specialty pharmacies and a specialty distributor in the U.S., as well as to its collaboration partner, Otsuka Pharmaceutical Co., Ltd., for distribution in various international markets. The company also reported a cash position of $351.8 million as of September 30, 2025, slightly down from $358.5 million at the end of 2024, reflecting ongoing investments and share repurchase activities.
In terms of strategic initiatives, Aurinia has been focused on expanding its product offerings and enhancing operational efficiencies. The company is developing aritinercept, a dual inhibitor for autoimmune diseases, and plans to initiate clinical studies by the end of 2025. The restructuring efforts, which included a 45% reduction in workforce, were aimed at sharpening the company's focus on LUPKYNIS growth and the development of new therapies. The company has also repurchased 12.2 million shares for $98.2 million in the first nine months of 2025, as part of its ongoing share repurchase program.
Looking ahead, Aurinia expects to continue leveraging its existing cash reserves and operational cash flows to fund future growth initiatives. The company anticipates that its SG&A expenses will remain lower in 2025 as it realizes the benefits of its restructuring efforts. However, it acknowledges that future funding needs may arise depending on the success of its commercialization strategies and overall market conditions.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in therapies for autoimmune diseases with high unmet needs. Its core product, LUPKYNIS (voclosporin), is the first FDA-approved oral treatment for adult lupus nephritis, marketed in the U.S. and licensed internationally. Aurinia develops novel immunosuppressants like AUR200 targeting B cell pathways. The company operates through direct sales and partnerships, leveraging proprietary patents and contract manufacturing to serve patients and healthcare providers globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.